Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the ACR Convergence Congress.

Read more at globenewswire.com